EI
MLTX icon

EAM Investors’s MoonLake Immunotherapeutics MLTX Stock Holding History

EAM Investors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,917
Closed -$1.19M – 327
2023
Q3 		$1.19M Hold
20,917
– – 0.23% 199
2023
Q2 		$1.07M Buy
+20,917
New +$563K 0.2% 232

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

EAM Investors's MLTX Position: Q4 2023 in Review

EAM Investors sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2023, closing a stake of 20,917 shares — an estimated $1.19M sold.

EAM Investors first reported a position in MLTX in Q2 2023 and held it in 2 quarters. The position peaked at $1.19M in Q3 2023. 125 funds tracked by Wall St. Rank hold MLTX as of Q4 2023.

  • EAM Investors reported no remaining MoonLake Immunotherapeutics position as of Q4 2023 after selling out during the quarter.
  • EAM Investors sold 20,917 MoonLake Immunotherapeutics shares in Q4 2023, an estimated $1.19M.
  • EAM Investors first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 2 quarters.
  • EAM Investors's MoonLake Immunotherapeutics position peaked at $1.19M in Q3 2023.
  • 125 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2023.

Based on EAM Investors's 13F filing for Q4 2023, filed 14 Feb 2024.